{
    "2018-01-10": [
        [
            {
                "time": "2023-01-10",
                "original_text": "Eli Lilly & Co. at J.P. Morgan: 5 Things Investors Will Want to Know",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "J.P. Morgan",
                        "Investors",
                        "Things to Know"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-01-10",
                "original_text": "Novo Nordisk's Ozempic Gets Canadian Approval for Diabetes",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Ozempic",
                        "Canadian Approval",
                        "Diabetes"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-01-10",
                "original_text": "Novo Nordisk's Ozempic Gets Canadian Approval for Diabetes",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Ozempic",
                        "Canadian Approval",
                        "Diabetes"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}